Company profile
AGOMAB THERAPEUTICS NV
NASDAQ:AGMBBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ONTUNISERTIB | phase2 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07118878 | phase1 | completed | 2025-08-06 | 2025-09-15 | Agomab Spain S.L.U. | A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants |
| NCT07862634 | phase2 | not_yet_recruiting | 2026-11-30 | 2028-10-31 | Agomab Spain S.L.U. | A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis |
| NCT05937386 | phase1 | completed | 2023-08-09 | 2023-09-06 | Agomab Spain S.L. | Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants |
| NCT07672574 | phase1 | recruiting | 2026-09-09 | 2026-09-26 | Agomab Spain S.L.U. | Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers |
| NCT07683325 | phase2 | recruiting | 2026-10-30 | 2028-12-31 | Agomab Spain S.L.U. | NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease |
FDA applications (0)
No records yet.